Munir Hazbun, MD
Critical Care Medicine · Dallas, TXNPI 1467492868
Payments from drug & device makers
Across 267 payments — averaging $30.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- GSK$1K
- Boehringer Ingelheim$467
- AstraZeneca$444
- Insmed, Inc.$320
- Baxter Healthcare$304
- plus $3K from 33 others
What the payments were for
- Travel & lodging$82110%
- Food & beverage$7,18089%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 17 | $1,971 |
| GSK | 59 | $1,113 |
| Boehringer Ingelheim | 20 | $467 |
| AstraZeneca | 26 | $444 |
| Insmed, Inc. | 17 | $320 |
| Baxter Healthcare | 16 | $304 |
| Sanofi | 8 | $302 |
| Novo Nordisk | 4 | $228 |
| Lilly USA, LLC | 7 | $222 |
| AOP Health US, LLC | 1 | $215 |
| Harmony Biosciences LLC | 1 | $179 |
| Inari Medical, Inc. | 1 | $154 |
| Paratek Pharmaceuticals, Inc. | 8 | $142 |
| ZOLL Respicardia, Inc. | 1 | $141 |
| Itamar Medical Inc | 4 | $139 |
| Pulmonx Corporation | 1 | $137 |
| Grifols USA, LLC | 6 | $137 |
| Philips North America LLC | 9 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $126 |
| AbbVie | 5 | $121 |
| Electromed, Inc. | 9 | $116 |
| Jazz Pharmaceuticals Inc. | 4 | $110 |
| Amgen | 6 | $108 |
| Actelion Pharmaceuticals US, Inc. | 4 | $92 |
| Pfizer | 4 | $87 |
| Merck | 4 | $76 |
| Regeneron Healthcare Solutions, Inc. | 2 | $74 |
| Resmed Corp | 1 | $54 |
| 3b Medical, Inc. | 2 | $51 |
| United Therapeutics Corporation | 2 | $49 |
| Mallinckrodt Hospital Products Inc. | 3 | $48 |
| Caris MPI, Inc. | 1 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Vifor Pharma, Inc. | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Stryker | 1 | $25 |
| Hospira, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$1,559
- Rapiblyk$429
- Wakix$179
- FLOWTRIEVER CATHETER, S$154
- CT THROMBECTOMY SYSTEM KIT$154
- remede System$141
- CHARTIS CATHETER$137
- ZEPHYR DELIVERY CATHETER$137
- ZEPHYR ENDOBRONCHIAL VALVE$137
- PULMONX CHARTIS TABLET CONSOLE$137
- ZEPBOUND$122
- DUPIXENT$122
- Ozempic$118
- NUCALA$116
How this compares
$8,055 in reported general payments places this provider in the 85th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 555 | $415,707 |
| OfevNintedanib Esylate | 26 | $324,552 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $171,445 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 179 | $126,793 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $32,694 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $16,340 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 39 | $6,485 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,350 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 152 | $3,791 |
| Montelukast Sodium | 385 | $2,712 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,603 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $1,462 |
| Ventolin HfaAlbuterol Sulfate | 21 | $1,352 |
| Fluticasone Propionate | 50 | $867 |
| Azithromycin | 92 | $758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,113 | $448,401619 claims |
| Boehringer IngelheimOfev | $467 | $324,55226 claims |
| Grifols USA, LLCProlastin C | $137 | $171,44513 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $444 | $143,133227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Dallas
- Gary WeinsteinDallas$121K
- Anthony OrtegonDallas$106K
- Thomas ArdilesDallas$57K
- Vaidehi KazaDallas$33K
- Badih Kabchi JitaniDallas$13K
- Rebecca DoebeleDallas$12K
- Humayun AnjumDallas$11K
- Sridhar BadireddiDallas$11K
- Cynthia ZamoraSan Antonio$6.4M
- Rishi RajLubbock$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.